Phadia Ab

Biomay Ag

Biomay Produktions- Und Handelsgesellschaft M.b.h.

Other

Pharmacia Diagnostics Ab

Biomay Produktions- Und Handelsaktiengesellschaft

Pharmacia Ab

Pharmacia & Upjohn Ab

Biomay Biotechnik Produktions Und Handelsgesellschaft M.b.h.

Valenta, Rudolf

Dietrich Kraft

Rudolf Valenta

Peter Valent

Susanne Vrtala

Wolfgang R Sperr

Hans Grönlund

Michael Breitenbach

Otto Scheiner

Luca Vangelista

Sylvia Laffer

Helmut Rumpold

Karin Pettenburger

Annalisa Pastore

Monika Grote

Heimo Breiteneder

Birgit Linhart

Markus Susani

Tanja Ball

Sabine Stummfoll

Christof Ebner

Sabine Stumvoll

Michael Duchene

Jonas Adriansson

Paolo Colombo

Kenneth Roux

Kerstin Westritschnig

Margarete Focke-Tejkl

Ines Swoboda

Susanne Spitzauer

Fatima Ferreira

Ursula Wiedermann

Peter Steinberger

Martin Himly

Katharina Blatt

Klaus Richter

Erik Högbom

Marianne Van Hage-Hamsten

Kenneth H Roux

Wolfgang Sperr

Hans Gr&ouml;nlund

Edwin Engel

Hans-Georg Eichler

Raffaela Campana

Hans Groenlund

Nadine Mothes

Margit Focke

Maria-Theresa Krauth

Alex Karlsson-Parra

Margarete Focke

Anna Twardosz

Petra Verdino

Walter Keller

Johan Roennelid

Sabine Flicker

Vera Mahler

Anna Gieras

Domenico Geraci

Giovanni Duro

Erik Hoegbom

Annalisa c/o Molecular Structure Div Pastore

Sabine Stummvoll

Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.

Hypallergenic mosaic antigens and methods of making same

Microparticles are disclosed which comprise a bead essentially consisting of a cross-linked carbohydrate and an antigen covalently linked thereto. The microparticle can be used for the treatment of disorders of the immune system and in diagnostic tests.

Microparticles comprising carbohydrate beads covalently linked with allergen

Methods for desensitization of a mammal suffering from IgE mediated allergy comprise the steps of: administering to said mammal a therapeutically effective amount of an immunogenic and hypoallergenic composition which comprises (i) a Phl p 6 molecule having an N-terminal truncation which makes the molecule at least lack IgE binding capacity, and/or (ii) a Phl p 6 molecule having a C-terminal truncation which makes the molecule at least lack IgE binding capacity, wherein the molecules of (i) and (ii), if employed in combination, together span the complete sequence of Phl p 6, and a pharmaceutically acceptable carrier.

Non-anaphylactic forms of grass pollen Ph1 p 6 allergen and their use

The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics:

Compound for treatment of allergy and asthma

Hybrid polypeptides comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein are disclosed. The hybrid polypeptides and polynucleotides coding therefor can be used as pharmaceutical compositions, in particular as vaccines.

Allergy vaccines containing hybrid polypeptides

A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.

Process for the preparation of hypoallergenic mosaic antigens

The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.

Non-anaphylactic forms of grass pollen Phl p 6 allergen and their use

The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.

The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.

Hypoallergenic allergy vaccines based on the timothy grass pollen allergen Phl p 7

The present invention relates to group 2 allergen specific IgE-Fabs and whole Ig molecules as well as use thereof. More precisely, the present invention relates to grass pollen specific IgE-Fabs (Phl p2) and reagents, kits and vaccines comprising these. The invention also relates to use of group 2 specific IgE-Fabs and whole Ig for, inter alia, diagnosis, therapy and prevention of type I allergy.

Group 2 allergen specific IgE-Fabs and use thereof

The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are identical to at least three amino acids which appear in close vicinity on the molecular surface of an allergenic protein, and said at least three amino acids are solvent-exposed amino acids in the allergenic protein. The invention also concerns a method for the preparation of the pharmaceutical composition.

Allergy vaccines and their preparation

A recombinant DNA molecule comprising a nucleotide sequence (I) which codes for a polypeptide displaying the antigenicity of one, two or more of the Phl p I epitope clones (28, 34, 41, 42, 43, 45, 50, 52, 64, 80, 85, 86, 95, 97, 98, 103, 108, 109, 113, 114), with the amino acid sequences defined in SEQ ID NOS: 5, 7, 9 and 12&#x2013;28, and preferably being derived from grasses or monocotyledonic plants, or a nucleotide sequence (II) which hybridizes with such a nucleotide sequence (I) under conditions of high, stringency. Polypeptides displaying the antigenicity of one, two or more of the Phl p I epitope clones (28, 34, 41, 42, 43, 50, 52, 64, 80, 85, 86, 95, 97, 98, 103, 108, 109, 113, 114). Recombinant expression vectors containing the recombinant molecule and host cells transformed with the vector. Diagnostic methods based on utilizing the polypeptides in immunoassays for humoral antibodies and cellular reactions.

Recombinant polypeptides having Ph1 p I epitope antigenicity and methods of diagnosing allergy in vitro

The present invention is drawn to an immunogen derived from a protein allergen, which is a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen which contains an IgG epitope partly but not wholly overlapping an IgE epitope of the protein allergen; b) a polymeric form of the fragment, in which the fragment constitutes the monomeric units; or c) a non-anaphylactic recombinant polymeric form of the protein allergen having 2&#x2013;10 monomeric units, in which the protein allergen constitutes the monomeric units. The present invention is further drawn to the use of the immunogen for in vitro diagnoses of type I allergy and hyposensitization.

Non-anaphylactic forms of allergens and their use

The invention relates to DNA molecules which code for the allergen Art v 1 or isoforms thereof, the sequence of the allergen, a method for the production of an Art v 1 molecule, a vector and a transformed host cell.

[object Object]

Growing community of inventors

Vienna, Austria

Dietrich Kraft